Rockeby biomed (ASX: RBY) has lodged a 501(k) submission for regulatory approval of its systemic candidiasis diagnostic SysCan3 with the United States Food and Drug Administration. [ + ]

Analysts say that the IPO market for biotech companies in Australia is healthy right now, and they don't foresee any problems in the near future. [ + ]

Bionomics (ASX: BNO) has set up a US subsidiary to hold intellectual property coming out of its US collaborations. [ + ]

Biosignal (ASX:BOS) and the Institute for Eye Research Ltd (IER) have reported interim results from recent in vitro trials of contact lenses with permanently attached furanones. [ + ]

Alchemia (ASX: ACL) will commence the preclinical studies necessary to take its lead anti-cancer compound into human clinical trials after positive results from studies in an animal model of lung cancer. [ + ]

The share price of Genetic Technologies (ASX: GTG) has risen over 50 per cent since the judge in GTG's lawsuit against Applera ruled largely in the company's favour during the Markman hearing last Thursday. [ + ]

Researchers from Monash University's Department of Epidemiology and Preventive Medicine are claiming to have revolutionised knee scans with the development of technology that harnesses the power of magnetic resonance imaging (MRI).

Significant abnormalities observed in cloned mice help reinforce the need to continue to avoid the reproductive cloning of humans, claims Dr Takumi Takeuchi, from Cornell University.

Ongoing research into how the mammalian genome works could lead to major advances in livestock production, according to CSIRO Livestock Industries' researcher, Dr Brian Dalrymple.

Monash researcher Dr Jamie Rossjohn has received a Prime Minister's award for his contribution to science.

Biotech consultant Dr Lyndal Thorburn has been named the 2004 Telstra Business Woman of the Year for the ACT. [ + ]

Shares of California-based Isis Pharmaceuticals rose as much as 13 per cent on Thursday after it said its experimental anti-cancer compound significantly delayed tumour growth and increased the rate of malignant cell death in cell and animal models. [ + ]

A New Zealand-based venture capital fund of between NZ$75-100 million (AUD$70-94.5 million), with a focus on agricultural biotech has been established by the venture capital arm of the NZ government and private collaborators Direct Capital and crown research institute AgResearch. [ + ]

NSW biomaterials company Avastra (ASX: AVS) is investigating the potential of its BioWeld technology -- which uses a protein solder activated by laser light to fuse together blood vessels -- as a drug delivery mechanism. [ + ]

CSIRO and the global industrial gas company the BOC Group have signed a deal to deliver to the international market a new environmentally-safe fumigant for treating soil, insect pests, weeds and diseases.